ID Source | ID |
---|---|
PubMed CID | 434695 |
CHEMBL ID | 1324767 |
CHEMBL ID | 2009804 |
CHEMBL ID | 1698288 |
SCHEMBL ID | 13856956 |
SCHEMBL ID | 16974412 |
MeSH ID | M0589198 |
Synonym |
---|
smr001565442 |
NCI60_003195 |
3-((9-amino-7-ethoxy-3-acridinyl)diazenyl)-2,6-pyridinediamine |
nsc354961 , |
nsc-354961 |
mls002701850 , |
NCGC00014809 , |
NCI354961 |
NCISTRUC2_001878 |
NCISTRUC1_001839 |
NCGC00097910-01 |
3-[(9-amino-7-ethoxyacridin-3-yl)diazenyl]pyridine-2,6-diamine |
CCG-37464 |
NCGC00014809-02 |
CHEMBL1324767 |
SCHEMBL13856956 |
CHEMBL2009804 |
CHEMBL1698288 |
cid_434695 |
3-[(9-amino-7-ethoxy-3-acridinyl)azo]pyridine-2,6-diamine |
3-[(9-azanyl-7-ethoxy-acridin-3-yl)diazenyl]pyridine-2,6-diamine |
[6-amino-3-(9-amino-7-ethoxy-acridin-3-yl)azo-2-pyridyl]amine |
bdbm80829 |
SCHEMBL16974412 |
E73463 |
3-((9-amino-7-ethoxyacridin-3-yl)diazenyl)pyridine-2,6-diamine |
HY-124675 |
681282-09-7 |
mycmi-6 |
CS-0087296 |
BS-49481 |
AKOS040733796 |
PD121549 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 3.9811 | 0.0126 | 10.6917 | 88.5700 | AID887 |
WRN | Homo sapiens (human) | Potency | 22.3872 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
USP1 protein, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 4.1989 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 5.0119 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.5893 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 7.0795 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
snurportin-1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 75.6863 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.5481 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0003 | 11.4484 | 31.6228 | AID900 |
Caspase-7 | Homo sapiens (human) | Potency | 3.9811 | 3.9811 | 18.5856 | 31.6228 | AID889 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 44.6684 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cardiac alpha tropomyosin | Sus scrofa (pig) | IC50 (µMol) | 12.6830 | 3.1910 | 3.1910 | 3.1910 | AID504742 |
troponin I, cardiac muscle | Homo sapiens (human) | IC50 (µMol) | 12.6830 | 3.1910 | 3.1910 | 3.1910 | AID504742 |
troponin T, cardiac muscle isoform 3 | Homo sapiens (human) | IC50 (µMol) | 12.6830 | 3.1910 | 3.1910 | 3.1910 | AID504742 |
troponin C, slow skeletal and cardiac muscles | Homo sapiens (human) | IC50 (µMol) | 12.6830 | 3.1910 | 3.1910 | 3.1910 | AID504742 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
histone-lysine N-methyltransferase NSD2 isoform 1 | Homo sapiens (human) | AC50 | 20.0000 | 0.2930 | 7.3070 | 19.4400 | AID1053173 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular space | Caspase-7 | Homo sapiens (human) |
nucleus | Caspase-7 | Homo sapiens (human) |
cytoplasm | Caspase-7 | Homo sapiens (human) |
cytosol | Caspase-7 | Homo sapiens (human) |
nucleus | Caspase-7 | Homo sapiens (human) |
nucleoplasm | Caspase-7 | Homo sapiens (human) |
cytosol | Caspase-7 | Homo sapiens (human) |
cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1683511 | Antiproliferative activity against human Mutu-1 assessed as reduction in cell viability measured after 2 hrs | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Ligand-based optimization and biological evaluation of N-(2,2,2-trichloro-1-(3-phenylthioureido)ethyl)acetamide derivatives as potent intrinsically disordered protein c-Myc inhibitors. |
AID1683512 | Antiproliferative activity against human ST486 assessed as reduction in cell viability measured after 2 hrs | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Ligand-based optimization and biological evaluation of N-(2,2,2-trichloro-1-(3-phenylthioureido)ethyl)acetamide derivatives as potent intrinsically disordered protein c-Myc inhibitors. |
AID1683513 | Antiproliferative activity against human Daudi assessed as reduction in cell viability measured after 2 hrs | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Ligand-based optimization and biological evaluation of N-(2,2,2-trichloro-1-(3-phenylthioureido)ethyl)acetamide derivatives as potent intrinsically disordered protein c-Myc inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |